Peptide RegulationDeveloping
FDA Is Reviewing Compounded Peptide-Clinic Favorites
FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.
Why now
The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026